Whitepaper
Simplify mRNA Production
June 2024
- Biopharmazeutik
- Datenaufzeichnung
- Parallele Reaktionen
- Sterilisation
mRNA vaccines have evolved through decades of research, starting in the early 1990s, with efforts focused on mRNA's potential as a vaccine platform. Challenges like instability were overcome in the 2000s, leading to breakthroughs in lipid nanoparticle delivery systems. The approval of the first mRNA vaccine in 2020 marked a transformative moment in vaccine history, showing mRNA's potential in providing rapid and effective solutions to diseases like COVID-19. Scaling up production poses challenges, but solutions like the Mya 4 Reaction station and Reactor-Ready system offer reliable platforms for consistent and high-quality mRNA output, bridging the gap between lab and industrial-scale production.
Autor: Heidolph